Please assess the completion status of the following clinical trial:

Trial Title: Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (ages 18 years or older) with diabetes mellitus~* Best corrected visual acuity worse than 20/40 but no worse than 20/800 in the study eye~* Best corrected visual acuity better than or equal to 20/800 in the fellow eye~* DME in the study eye (eye scheduled to undergo cataract surgery) as documented on OCT as a center point thickness of at least 250 microns no more than 3 weeks prior to cataract surgery~* No prior laser photocoagulation in the study eye for at least 4 months prior to cataract surgery~* Women of child-bearing potential who are interested in participating in this study will use two effective forms of contraception prior to initiation of pegaptanib and then throughout the remainder of the study. For women of childbearing potential, results from a urine pregnancy test will be obtained prior to each injection with pegaptanib. Urine samples will be disposed of after the test is performed.~Exclusion Criteria:~* History of intravitreal steroid (triamcinolone) injection into the study eye within 4 months prior to cataract surgery~* Macular edema due to non-diabetic etiologies such as vein occlusion~* Retinal diseases that preclude evaluation of the macula for edema (e.g., macular hole)~* Media opacity will not be an exclusion criterion provided that the investigator can assess the presence or absence of DME on OCT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).